The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jan 2022 12:58

RNS Number : 8143X
Diurnal Group PLC
07 January 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BDB6Q760

Issuer Name

DIURNAL GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Pendal Group Limited

City of registered office (if applicable)

Sydney

Country of registered office (if applicable)

Australia

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

06-Jan-2022

6. Date on which Issuer notified

07-Jan-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.987000

0.000000

4.987000

8435000

Position of previous notification (if applicable)

5.032453

0.000000

5.032453

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BDB6Q760

0

8435000

0.000000

4.987000

Sub Total 8.A

8435000

4.987000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Pendal Group Limited

4.987000

4.987000%

J O Hambro Capital Management Limited

4.987000

4.987000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-Jan-2022

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUPUQAGUPPGPM
Date   Source Headline
7th Mar 20222:30 pmRNSScottish Medicines Consortium Update
2nd Mar 20227:00 amRNSRegulatory update on oral native testosterone
1st Mar 202210:23 amRNSTotal Voting Rights
24th Feb 202212:00 pmRNSNotice of Interim Results
10th Feb 20227:00 amRNSFirst patient dosed in Phase 2 trial
9th Feb 20227:00 amRNSIssue of Long-Term Incentive Plan awards
1st Feb 20227:00 amRNSTotal Voting Rights
31st Jan 20221:26 pmRNSPostponement of R&D Day
26th Jan 20227:00 amRNSTrading Update
24th Jan 20227:00 amRNSDiurnal to participate in Edison “Open House”
11th Jan 20227:00 amRNSOperational update
7th Jan 202212:58 pmRNSHolding(s) in Company
13th Dec 202112:46 pmRNSBlock Admission Application
2nd Dec 20217:00 amRNSNotice of R&D Day
19th Nov 202111:43 amRNSResults of AGM
16th Nov 20217:00 amRNSAlkindi approved for use in Switzerland
15th Nov 20215:20 pmRNSEton enters into US co-promotion deal
15th Nov 20217:00 amRNSDirectorate Change
8th Nov 20219:16 amRNSHolding(s) in Company
15th Oct 202111:17 amRNSHolding(s) in Company
14th Oct 20217:01 amRNSAppointment of Joint Corporate Broker
14th Oct 20217:00 amRNSAgreement signed with ExCEEd Orphan for CEE
11th Oct 20217:00 amRNSPhase 1 data for DITEST published in EJE
8th Oct 202112:24 pmRNSExercise of Options, Issue of Equity and TVR
7th Oct 202111:15 amEQSHardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum
6th Oct 20213:53 pmRNSPosting of Annual Report and Notice of AGM
30th Sep 202112:08 pmRNSHolding(s) in Company
29th Sep 20212:35 pmRNSHolding(s) in Company
17th Sep 20217:00 amRNSHardman & Co Life Sciences Investor Forum
16th Sep 202110:15 amEQSHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials
15th Sep 20219:17 amRNSDirector Dealings
14th Sep 20217:00 amRNSResults for the year ended 30 June 2021
13th Sep 20217:00 amRNSCommercial launch of Efmody in the UK
1st Sep 20217:00 amRNSDiurnal launches Efmody in Germany and Austria
19th Aug 20217:00 amRNSFull Year Results Investor Presentation
12th Aug 20217:20 amEQSHardman & Co Video Event | Diurnal Group plc - Investor Forum
2nd Aug 20217:00 amRNSGrant of Deferred Share Awards
28th Jul 20217:00 amRNSBusiness and Trading Update
14th Jul 20217:00 amRNSDirector Dealings
12th Jul 20217:00 amRNSAgreement from US FDA on SPA for Chronocort
9th Jul 20218:30 amRNSDirector Dealings and Issue of Equity
7th Jul 20217:00 amRNSNotice of Full Year Results
5th Jul 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
2nd Jul 20217:00 amRNSMarketing Authorisation for Efmody in GB from MHRA
29th Jun 20217:00 amRNSDistribution agreement with Er-Kim
2nd Jun 202112:19 pmRNSDirector Dealings
1st Jun 20217:00 amRNSDiurnal triggers milestone payments from Citrine
28th May 20212:33 pmRNSEuropean Commission approval received for Efmody
13th May 20217:00 amRNSCorrection: Director Dealings
12th May 20215:32 pmRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.